I am delighted to give you the #SITC24 presentation details of the first-in-human, international study of this first-in-class bispecific antibody that targets TCR Vbeta chain and brings with it IL-2.

So proud of Chrystal! @sitcancer.

RT @sitcancer: Applications are open for SITC Sparkathon 2026 to be held on March 23–25, 2026, in Tucson, AZ. This year's topic focuses on….

I am so proud of the NCI researchers and team that led to this approval! Also proud of our CRADA partners at @Precigen. This is the first FDA approval for RRP, bringing hope and a voice to patients with this debilitating condition. @sitcancer .

Delighted to take a run in the Boston Commons this am. Skies still cloudy after the storm, but the sun will be out, I know it. ⁦@JennGuerriero⁩ ⁦@sitcancer⁩

RT @sitcancer: Share your research and discuss publication with @jitcancer Meet the Editor Session with Dr. Marcela V. Maus, co-Section Edi….

RT @oncodaily: SITC (@sitcancer) - The Advances in Cancer Immunotherapy. #OncoDaily #Oncology #Cancer #Health #Med….

RT @Dr_RaviMadan: 3 consults this wk. PSA 1 or well below with no significant change. On ADT+ARPI, w/recommendation for chemo based on #PSM….

RT @BcellBruno: Don't forget to join us tomorrow! #Bcells #TLS.

RT @fireflyann: @gulleyj1 @MyOncology @NickTscherniaMD @annwsilkmd @ClaireFriedma19 @lillian_siu @sonpavde @mbilusic @sitcancer @theNCI Con….

RT @GIMedOnc: #GI25 .Is it the hardest to pronounce name of any antibody? Yes. It is also probably the best new treatment for GI malignanc….

RT @MyOncology: Marengo Therapeutics is proud to announce that we received FDA Fast Track Designation for our First-in-Class Invikafusp Alf….

RT @NCIDirector: If you like learning about AI changing cancer care, listen to this episode from @GovCIOMedia’s Cancer HealthCast about @th….

What an incredible group of people to work with! ⁦@sitcancer⁩ ⁦@PatrickHwuMD⁩ ⁦@JennGuerriero⁩

RT @DemariaLab_WCM: Join the SITC Run Club for the 2025 AACR Runners for Research 5K Run/Walk in support of Cancer Research! https://t.co/….

Looking forward to the Immuno-Oncology 360° Summit, happening March 24-26, 2025, in Boston! #IO360Summit

Love working with @jitcancer and delighted that it remains the #1 journal for immunotherapy of cancer both by impact factor and by number of publications.

For more reading. 👉

And I have so many people to thank for helping on this study. Certainly I thank my wonderful co-investigators, the patients and their families and the incredible people at Marengo Therapeutics (.

This new class of #immunotherapy shows .👉selective expansion of Vbeta T-cells that may have a unique biology.👉manageable safety profile.👉single agent activity in heavily pretreated patients